Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13477994 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18177084 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19522921 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19733545 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL22624856 | 0.99 | FAP (0.40) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL22970116 | 0.97 | MAP1LC3B (0.40) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL17210030 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL24438134 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL21131517 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL16730795 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| EP-3092256-B1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-05-18 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-09-28 | — | — | US | disclosed |
| EP-3763742-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2021-01-13 | — | — | EP | disclosed |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-10780180-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-09-22 | — | — | US | disclosed |
| US-20200276327-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3189082-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2020-08-19 | — | — | EP | disclosed |
| US-10328158-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-06-25 | — | — | US | disclosed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | disclosed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | disclosed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | disclosed |
| WO-2016034085-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-03-10 | — | — | WO | disclosed |
| WO-2015103989-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103987-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103990-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | FAP 163/4885MAP1LC3B 445/4885SIRT2 2074/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | FAP 708/4885MAP1LC3B 1117/4885SIRT2 2287/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | FAP 886/4885MAP1LC3B 138/4885SIRT2 2085/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | FAP 160/4885MAP1LC3B 1102/4885SIRT2 2297/4885 |
| US-10328158-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | FAP 163/4885MAP1LC3B 445/4885SIRT2 2074/4885 |
| US-20200276327-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | ERBB2, EGFR, TP53 | FAP 765/4885MAP1LC3B 595/4885SIRT2 1950/4885 |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | CD274, PDCD1LG2, PDCD1 | FAP 1579/4885MAP1LC3B 182/4885SIRT2 1763/4885 |
| US-10780180-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | FAP 163/4885MAP1LC3B 445/4885SIRT2 2074/4885 |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | FAP 163/4885MAP1LC3B 445/4885SIRT2 2074/4885 |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | ERBB2, EGFR, TP53 | FAP 765/4885MAP1LC3B 595/4885SIRT2 1950/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | FAP 1579/4885MAP1LC3B 182/4885SIRT2 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.